Biotechnology

Lyell Immunopharma

Lyell Immunopharma released FY2026 Q1 earnings on May 6 (EST), actual revenue USD 2 K (forecast USD 4.4 K), actual EPS USD -1.104 (forecast USD -2.364)

Lyell Immunopharma released FY2025 Q4 earnings on March 12 (EST), actual revenue USD 6K (forecast USD 20.33K), actual EPS USD -6.8623 (forecast USD -2.232)

Lyell Immunopharma released FY2025 earnings on March 12 (EST), actual revenue USD 36 K (forecast USD 36.2 K), actual EPS USD -16.0561 (forecast USD -10.53)

Lyell Immunopharma released FY2025 Q3 earnings on November 12 (EST), actual revenue USD 15K (forecast USD 0), actual EPS USD -2.1264 (forecast USD -2.6425)

Lyell Immunopharma released FY2025 9 Months Earnings on November 12 EST, with actual revenue of USD 30 K and EPS of USD -8.5528

Lyell Initiates Phase III Clinical Trial for CAR T Cell Therapy in Aggressive B-Cell Lymphoma

Lyell Immunopharma released FY2025 Q2 earnings on August 12 (EST), actual revenue USD 8 K (forecast USD 0), actual EPS USD -2.8854 (forecast USD -3.5833)

Lyell Immunopharma released FY2025 Semi-Annual Earnings on August 12 (EST), actual revenue USD 15K, actual EPS USD -6.422

Lyell Immunopharma Issues 625,000 Shares to ImmPACT Bio

HC Wainwright Raises Lyell Immunopharma's Target Price to $10

Lyell Immunopharma Participates in HCW@Home to Share LYL314 Clinical Data

Lyell Immunopharma Announces Positive Clinical Trial Data

Lyell Immunopharma Inc. Confirms Mark Bachleda as Beneficial Owner and Director

Lyell Immunopharma Inc Appoints Key Executives to Enhance Clinical and Commercial Capabilities

Lyell Executives to Attend Goldman Sachs Global Healthcare Conference

Lyell Immunopharma Sees Significant Short Interest Increase, Insiders Buy Stock

Lyell Immunopharma Annual General Meeting Held

Lyell Immunopharma released FY2025 Q1 earnings on May 13 (EST), actual revenue USD 7K (forecast USD 0), actual EPS USD -3.5374 (forecast USD -3.6)

Lyell Immunopharma Reports Reduced Q1 2025 Net Loss

Lyell Immunopharma Inc Expected to Report 18 Cent Loss Per Share in Q1 2025

OPTIMI HEALTH CORP

HCW Biologics

Silexion Therapeutics

Vida Global

GCL Global

BiomX

MetaVia

Micware

MicroAlgo

LYEL

Mitchell Kapoor from H.C. Wainwright has reiterated a Buy rating on Lyell Immunopharma with a price target of $45. The rating is based on Lyell's leadership in the CD19/20 CAR-T space and the progress of its lead asset, ronde-cel. Kapoor highlights the company's pivotal LBCL programs and strong cash balance, which extends its runway into 2027. Needham also maintains a Buy rating with a $44 price target.

Tip Ranks

Lyell Gains Buy Rating on Leadership in CD19/20 CAR-T and Ronde-cel Progress; Analyst Reiterates $45 Price Target

Earnings Watch

Lyell Immunopharma | 8-K: FY2026 Q1 Revenue Misses Estimate at USD 2 K

Lyell Immunopharma | 10-Q: FY2026 Q1 Revenue Misses Estimate at USD 2 K

In South San Francisco on May 6, 2026, Lyell Immunopharma, Inc. (Nasdaq: LYEL) shared their financial updates for the first quarter of 2026. The company, specializing in innovative CAR T-cell therapies for cancer patients, announced key business achievements during this period. This late-stage clinical company is making significant strides with its pipeline of next-generation CAR T-cell therapies. The report for the quarter ending on March 31, 2026, underlined the firm's progress and financial standing.

Unusual Whales

Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2026

Lyell Immunopharma (NASDAQ:LYEL) is set to release its Q1 2026 earnings on May 12, with analysts predicting a loss of $2.3650 per share and revenue of $0.0060 million. The company previously reported a loss of $7.68 EPS for Q1 2025, missing estimates. LYEL shares recently traded at $20.37, down $0.35, with a market cap of $475.23 million. Analysts have mixed ratings on the stock, with a consensus rating of "Moderate Buy" and a target price of $43.00. Insider trading activity has seen significant share sales recently.

Market Beat

Barclays

Lyell Immunopharma (LYEL) to Release Quarterly Earnings on Tuesday

Robert W. Baird upgraded Lyell Immunopharma (NASDAQ:LYEL) to a "strong-buy" rating. The company has seen mixed ratings from analysts, with one strong buy, three buys, and two sells. Currently, it has a consensus rating of "Moderate Buy" and a price target of $43.00. The stock opened at $20.83, up 5.6%, with a market cap of $485.96 million. Recent earnings showed a loss of ($7.68) EPS, missing estimates. Insiders have sold shares recently, and institutional investors own 66.05% of the stock.

GlaxoSmithKline plc

Arcadian Asset

GSK plc Sponsored ADR

Lyell Immunopharma (NASDAQ:LYEL) Upgraded by Robert W. Baird to Strong-Buy Rating

Bank of America Securities analyst Jason Zemansky has reaffirmed a Sell rating on Lyell Immunopharma (LYEL) with a price target of $12.00. Zemansky, a 5-star analyst, has an average return of 21.3% and a 58.82% success rate. The overall analyst consensus for Lyell Immunopharma is a Moderate Buy, with an average price target of $36.80.

Bank of America

Biogen

Cytokinetics

Bridgebio Pharma

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

Bank of America Securities Reaffirms Their Sell Rating on Lyell Immunopharma (LYEL)

Lyell Immunopharma(LYEL.US)